Hypertension Management: 2026 ACC/AHA Blood Pressure Targets and Treatment Updates

Updated Blood Pressure Targets: The Evidence Base

The SPRINT trial demonstrated that intensive systolic BP control (target less than 120 mmHg) reduced the primary composite cardiovascular endpoint by 25% (HR 0.75, 95% CI 0.64-0.89) and all-cause mortality by 27% compared to standard treatment (target less than 140 mmHg) in patients with elevated cardiovascular risk. The STEP trial extended these findings to elderly patients aged 60-80, showing that a target of 110-130 mmHg reduced cardiovascular events by 26% compared to 130-150 mmHg. The 2026 guidelines now recommend a systolic target below 130 mmHg for most adults and below 120 mmHg for those at high cardiovascular risk without contraindications.

First-Line Pharmacotherapy Selection

Three drug classes remain first-line: ACE inhibitors or ARBs, calcium channel blockers (specifically amlodipine or long-acting nifedipine), and thiazide-like diuretics (chlorthalidone or indapamide preferred over hydrochlorothiazide based on the ALLHAT and CLICK trials showing superior 24-hour BP lowering). The ESPRIT trial demonstrated that initial combination therapy with an ARB plus amlodipine achieved target BP in 80% of patients at 6 months versus 60% with monotherapy, supporting the guideline recommendation to start combination therapy for stage 2 hypertension (BP 140/90 mmHg or above).

Combination Therapy: Optimizing the Regimen

The preferred two-drug combination is an ACE inhibitor or ARB plus a calcium channel blocker, based on the ACCOMPLISH trial showing superiority of benazepril/amlodipine over benazepril/hydrochlorothiazide for cardiovascular outcomes (HR 0.80, p = 0.002). Single-pill combinations improve adherence by 20-30% compared to free-drug equivalents. For patients requiring three-drug therapy, the standard triple combination is ACE inhibitor or ARB plus CCB plus thiazide-like diuretic.